Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy : vimarsana.com

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy

Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Approval to Proceed with Medium Dose Cohort Dosing Malvern, Pa., April 05, 2024 -- Ocugen, Inc. , a...

Related Keywords

United States , Americans , Peter Chang , Linkedin , Head Of Communications , Exchange Commission , Ocugen Inc , Established Low Dose , Tolerable Dose , Medium Dose Cohort , Safety Monitoring Board , Huma Qamar , Chief Medical Officer , Orphan Receptor , Private Securities Litigation Reform Act , Markets ,